Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Executive Summary
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
You may also be interested in...
Merck & Co’s TROP2 Partner Trumpets Phase III Success In TNBC
Merck & Co's antibody-drug conjugates pact with Kelun is progressing well and the lead candidate of the pact, the TROP2-targeting candidate codenamed SKB264/MK-2870, has significantly improved progression-free survival in triple-negative breast cancer patients in a late-stage trial in China.
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Big Antibody Deals Offer Hope Amid Challenging Times For China Biotech
Recent antibody mega-deals are providing a rare bright spot for the embattled China biotech sector, amid sharply rising COVID-19 deaths in the country that indicate rebound and recovery could take longer than previously expected.